Anti-CGRP Migraine Drugs Don't Just Stop Headaches — They Prevent the Whole Attack

In 80 chronic migraine patients who responded well to anti-CGRP antibodies (erenumab, fremanezumab, or galcanezumab), the drugs prevented not just the headache but also the anticipatory and accompanying symptoms of migraine. Most patients experienced complete prevention without evidence of an attack starting and being aborted. Only 10–12.5% reported residual prodromal symptoms without headache, and 1.3–8.8% had accompanying symptoms without headache. All patients with aura reported decreased aura incidence. Additional effects included sleep changes (51.2%), increased appetite (20%), weight gain (18.8%), reduced stress (45%), reduced anxiety (26.3%), and fewer panic attacks (15%).

This was an explorative, prospective, questionnaire-based study of 80 chronic migraine patients who had achieved a sustained response to anti-CGRP antibody treatment (≥50% reduction in Migraine Disability Assessment Score and ≥30% reduction in monthly migraine days at three months). Patients completed questionnaires about prodromal symptoms, accompanying symptoms, aura, and neurological/psychiatric changes during treatment with erenumab, fremanezumab, or galcanezumab.

Most migraine research focuses on headache frequency and severity, but migraine is far more than a headache — it includes prodromal symptoms, aura, nausea, light sensitivity, and cognitive changes. This study shows anti-CGRP antibodies don't just suppress pain; they appear to prevent the entire migraine cascade from initiating, which tells us something fundamental about how CGRP drives the disease.

Anti-CGRP antibodies revolutionized migraine prevention, but most clinical trials only measured headache days. This study reveals the drugs' effects go deeper — they appear to shut down the entire migraine cascade, not just the pain phase. This has implications for understanding migraine as a whole-brain disorder driven by CGRP signaling, not just a pain condition.

The study only included treatment responders (patients with ≥50% disability reduction), so results don't apply to non-responders. The sample size of 80 is modest. As a questionnaire-based study, it relies on patient recall. There was no placebo control group, so some improvements could reflect placebo effects or natural variation. The study did not distinguish effects between the three different antibodies.